Patents Examined by Binta M. Robinson
-
Patent number: 8143293Abstract: Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyclosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.Type: GrantFiled: April 18, 2008Date of Patent: March 27, 2012Assignee: Deciphera Pharmaceuticals, LLCInventors: Daniel L. Flynn, Peter A. Petillo, Michael D. Kaufman
-
Patent number: 7998984Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.Type: GrantFiled: May 7, 2007Date of Patent: August 16, 2011Assignee: AstraZeneca ABInventors: Peter Hansen, Karolina Lawitz, Matti Lepistö, Hans Lönn, Asim Ray
-
Patent number: 7960554Abstract: Ambient-temperature molten salts of formula (I): wherein Y+ is a cation selected from the group consisting of an ammonium ion, a sulfonium ion, a pyridinium ion, a(n) (iso)thiazolium ion, and a(n) (iso)oxazolium ion that may be optionally substituted with C1-10 alkyl and/or C1-10 alkyl having ether linkage, provided that the above cation has at least one substituent of —CH2Rf1 or —OCH2Rf1 (wherein Rf1 is C1-10 perfluoroalkyl); Rf2 and Rf3 are independently C1-10 perfluoroalkyl or may together form C1-4 perfluoroalkylene; and X is —SO2— or —CO—.Type: GrantFiled: April 16, 2007Date of Patent: June 14, 2011Assignee: Toyota Jidosha Kabushiki KaishaInventor: Teruo Umemoto
-
Patent number: 7919506Abstract: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.Type: GrantFiled: January 3, 2007Date of Patent: April 5, 2011Assignee: Pfizer Inc.Inventors: George Chang, Ravi S. Garigipati, Bruce Lefker, David A. Perry, Dongxiang Zeng
-
Patent number: 7910608Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.Type: GrantFiled: July 19, 2007Date of Patent: March 22, 2011Assignee: Theravance, Inc.Inventors: Mathai Mammen, Yu-Hua Ji, YongQi Mu, Craig Husfeld, Li Li
-
Patent number: 7897621Abstract: The present invention relates to compounds formula I: and pharmaceutically acceptable salts thereof, wherein R1 to R8 are as defined in the description and claims for use as HDL-cholesterol raising agents in the treatment and/or prophylaxis of diseases or disorders that can be treated with such agents such as dyslipidemia.Type: GrantFiled: March 16, 2009Date of Patent: March 1, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Paul Hebeisen, Constantinos G. Panousis, Stephan Roever, Pius Waldmeier, Matthew Wright
-
Patent number: 7879863Abstract: The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 29, 2006Date of Patent: February 1, 2011Assignee: Ajinomoto Co., Inc.Inventors: Munetaka Tokumasu, Masayuki Sugiki, Haruko Hirashima, Hideki Matsumoto, Toshihiko Yoshimura, Yasuko Nogi, Mitsuo Takahashi, Manabu Kitazawa, Akiko Oonuki, Naoyuki Fukuchi, Yoichiro Shima
-
Patent number: 7879884Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.Type: GrantFiled: May 14, 2008Date of Patent: February 1, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Frederick Brookfield, Lothar Kling, Ulrike Reiff, Wolfgang Von der Saal, Thomas Von Hirschheydt
-
Patent number: 7875636Abstract: The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.Type: GrantFiled: April 11, 2007Date of Patent: January 25, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: James C. Barrow, Thomas S. Reger, Zhi-Qiang Yang
-
Patent number: 7872026Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radical of formulae (a) to (c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively, into cosmetic compositions.Type: GrantFiled: June 8, 2006Date of Patent: January 18, 2011Assignee: Galderma Research & DevelopmentInventors: Thibaud Biadatti, Olivier Roye
-
Patent number: 7842813Abstract: The present invention relates generally to novel methods for the synthesis of O-[5-(4-amino-thiazol-2-yl)-pyridin-2-ylmethyl]-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acceptable salts in PCT Application WO 03/097659 A1.Type: GrantFiled: May 8, 2009Date of Patent: November 30, 2010Assignee: Enanta Pharmaceuticals, Inc.Inventors: Datong Tang, Yinglin Han, Yanhe Huang, Ly Tam Phan, Yat Sun Or, Zhe Wang
-
Patent number: 7838523Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.Type: GrantFiled: September 11, 2007Date of Patent: November 23, 2010Assignee: CGI Pharmaceuticals, Inc.Inventors: Peter A. Blomgren, Seung H. Lee, Scott A. Mitchell, Jianjun Xu, Aaron C. Schmitt, Jeffrey E. Kropf, Kevin S. Currie
-
Patent number: 7834028Abstract: The invention relates to novel pyrazolo-tetrahydropyridines compounds and their use as orexin receptor antagonists.Type: GrantFiled: April 25, 2007Date of Patent: November 16, 2010Assignee: Actelion Pharmaceuticals Ltd.Inventors: Hamed Aissaoui, Christoph Boss, Markus Gude, Ralf Koberstein, Thierry Sifferlen
-
Patent number: 7829556Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: June 20, 2008Date of Patent: November 9, 2010Assignee: Sirtris Pharmaceuticals, Inc.Inventors: Jean Bemis, Jeremy S. Disch, Michael Jirousek, Walter Joseph Lunsmann, Pui Yee Ng, Chi B. Vu
-
Patent number: 7829730Abstract: The present invention provides a process for producing a methylene disulfonate compound in a simple manner at low cost. The present invention provides a process for producing a methylene disulfonate compound represented by General Formula (2) comprising: reacting, in the presence of a dehydrating agent, a formaldehyde compound with a sulfonic acid compound represented by General Formula (1): wherein R1 and R2 are independently a hydrogen atom or a C1-4 alkyl group whose hydrogen atom may be substituted with halogen atom; n is an integer from 1 to 4; and when n is an integer from 2 to 4, n R1s and n R2s may be the same or different: wherein, R1, R2, and n are the same as those described above for General Formula (1).Type: GrantFiled: April 4, 2007Date of Patent: November 9, 2010Assignee: Sumitomo Seika Chemicals Co., Ltd.Inventors: Takehiro Hiyama, Takeshi Takeuchi, Hidehiko Myoken, Hirokazu Kagano
-
Patent number: 7820698Abstract: Compounds of formula (I): wherein n, A, R1, and R2 are defined in the specification, are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and for treating certain conditions.Type: GrantFiled: April 14, 2009Date of Patent: October 26, 2010Assignee: Chiesi Farmaceutici S.p.A.Inventors: Andrea Rizzi, Elisabetta Armani, Ilaria Peretto, Elena La Porta
-
Patent number: 7816380Abstract: ?-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; R1, R2 and R3 are each independently selected from H, halogen and OH; or R1 and R2 attached to the same carbon atom together represent oxo; R4 is H or methyl; R5 is Cl or I2; R6 is selected from —CO2—C1-4alkyl, —O—C1-4alkyl, —O—C1-4haloalkyl, 2-methyltetrazol-5-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 5-halomethyl-1,2,4-oxadiazol-3-yl, 3-halomethyl-1,2,4-oxadiazol-5-yl, tetrazol-5-yl, 5-halomethyl-1,2,3-triazolyl, and 5-methyl-1,2,3-triazolyl; R7 and R8 are each independently Cl or I2; and n is 0 or 1, are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.Type: GrantFiled: May 30, 2006Date of Patent: October 19, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Michael R. Wood
-
Patent number: 7816352Abstract: The present invention provides compounds that act as selective agents to protect against unintentional cell death or tissue damage and can relieve side effects of cancer treatment such as, for example, oral mucositis, hair loss, diarrhea due to damage to the gastrointestinal epithelium, and myelosuppression. In addition, these compounds can be used to prevent premature cell death when the cell death is caused by signals from damaged cells, for example, signals generated as the result of a traumatic incident or an ischemic episode.Type: GrantFiled: March 10, 2006Date of Patent: October 19, 2010Assignee: The Regents of The University of CaliforniaInventors: Dennis A. Carson, Howard B. Cottam, Sylvie Barchéchath, Mary Patricia Corr
-
Patent number: 7816378Abstract: The present invention is directed to cyclic ketal compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.Type: GrantFiled: July 28, 2006Date of Patent: October 19, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Philippe G. Nantermet, Joseph P. Vacca
-
Patent number: 7807692Abstract: Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.Type: GrantFiled: June 30, 2006Date of Patent: October 5, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: James F. Dropinski, Peter T. Meinke, Guo Q. Shi, Yong Zhang